Pharmacokinetic evaluation of oral levofloxacin in human immunodeficiency virus-infected subjects receiving concomitant antiretroviral therapy.
The purpose of this study was to evaluate the pharmacokinetics (PK) profile of oral levofloxacin in human immunodeficiency virus-positive patients in steady-state treatment with nelfinavir (NFV) or with efavirenz (EFV) and to determine the effects of levofloxacin on the PK parameters of these two antiretroviral agents. For levofloxacin, plasma samples were obtained at steady state during a 24-h dosing interval. Plasma NFV and EFV concentrations were evaluated before and after 4 days of levofloxacin treatment. Levofloxacin PK do not seem affected by NFV and EFV. There was no significant difference between NFV and EFV plasma levels obtained with and without levofloxacin.
Villani
P
P
Department of Pharmacology, IRCCS Policlinico S. Matteo, Pavia, Italy.
Viale
P
P
Signorini
L
L
Cadeo
B
B
Marchetti
F
F
Villani
A
A
Fiocchi
C
C
Regazzi
M B
MB
Carosi
G
G
D000284:Administration, Oral; D000480:Alkynes; D019380:Anti-HIV Agents / Q000494:pharmacology / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000493:pharmacokinetics*; D048588:Benzoxazines; D015331:Cohort Studies; D003521:Cyclopropanes; D004347:Drug Interactions; D015658:HIV Infections / Q000188:drug therapy / Q000378:metabolism*; D006801:Humans; D064704:Levofloxacin; D019888:Nelfinavir / Q000494:pharmacology / Q000627:therapeutic use; D015242:Ofloxacin / Q000493:pharmacokinetics*; D010078:Oxazines / Q000494:pharmacology / Q000627:therapeutic use; D011446:Prospective Studies
D000480:Alkynes; D019380:Anti-HIV Agents; D000890:Anti-Infective Agents; D048588:Benzoxazines; D003521:Cyclopropanes; D010078:Oxazines; D064704:Levofloxacin; D015242:Ofloxacin; D019888:Nelfinavir; C098320:efavirenz